PDL-1/PD1 inhibitors: antibody or antinobody?

Future Oncol. 2017 Aug;13(19):1669-1671. doi: 10.2217/fon-2017-0215. Epub 2017 Aug 23.

Authors

Fouad Aoun¹, Elie El Rassy², Tarek Assi², Joseph Kattan²

Affiliations

¹ Department of Urology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
² Department of Medical Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

PMID: 28831825
DOI: 10.2217/fon-2017-0215

No abstract available

Keywords: PD-1; PDL-1; biomarkers; immunotherapy; oncology.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents, Immunological / pharmacology*
Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors*
B7-H1 Antigen / metabolism
Biomarkers, Tumor
Humans
Neoplasms / drug therapy*
Neoplasms / immunology
Neoplasms / metabolism
Neoplasms / mortality
Prognosis
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / metabolism
Treatment Outcome

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
B7-H1 Antigen
Biomarkers, Tumor
Programmed Cell Death 1 Receptor